← 프로그램 목록
ApprovedRecruiting

Product (Anti-Tumor Necrosis Factor Alpha Drug)

R.Bos

비교

Anti-Tumor Necrosis Factor Alpha Drug (Product)(R.Bos)은 Rheumatoid Arthritis 표적 치료제로, Rheumatoid Arthritis 영역에서 개발·상용화 중입니다. 작용기전: target toxicity, as further supported by transcriptomic analysis revealing downregulation of fibrosis- and metabolism-related pathway. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 1.8% (ClinicalTrials.gov NCT00124982). 차별점: novel series of small-molecule TRPV4 antagonist discovered via high-throughput screening and optimized for potency, selectivi.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 13일 (1일 전)PK/독성 2026년 7월 13일 (1일 전)

Rheumatoid Arthritis

Rheumatoid Arthritis

Recruiting

Technology

구조모아 · StructureMoa에서 구조 검색

CAR-T cell product quality and long-term functionality

lipid nanoparticle

novel series of small-molecule TRPV4 antagonist discovered via high-throughput screening and optimized for potency, selectivi

Mechanism of Action

target toxicity, as further supported by transcriptomic analysis revealing downregulation of fibrosis- and metabolism-related pathway

CDCA), a naturally occurring bile acid, has demonstrated neuroprotective properties through activation

apoptosis, and improving cardiac function

biomarkers, and well-designed clinical trials with vascular or cardiovascular endpoints are required before c

downregulation and suppression of epithelial-mesenchymal transition

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 67건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 4 · Phase 3
  • Status: Completed · Unknown status · Recruiting
  • 주요 endpoint: Five-year Cumulative Incidence of Serious Adverse Events and Serious Infectious Events · Five-year Cumulative Incidence for Events of Medical Interest (EMIs) · Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Psoriasis Score of 0 (Clear) or 1 (Almost Clear) · Percentage of Participants With a Patient's Global Assessment of Psoriasis Score of 0 or 1 · Percentage of Participants With a Dermatology Life Quality Index (DLQI) Response
  • 등록된 결과: ORR 1.8%
  • 핵심: The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Anti-Tumor Necrosis Factor Alpha Drug (Product)은 어떤 치료제인가요?
Anti-Tumor Necrosis Factor Alpha Drug (Product)(R.Bos)은 Rheumatoid Arthritis 표적 항체로, Rheumatoid Arthritis 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Anti-Tumor Necrosis Factor Alpha Drug (Product)의 임상 단계는?
Anti-Tumor Necrosis Factor Alpha Drug (Product)의 현재 단계는 Approved입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.